- Home
- TAC vs DNLI Comparison
TAC vs DNLI Comparison
Compare TAC & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TAC | DNLI |
|---|---|---|
| Founded | 1909 | 2013 |
| Country | Canada | United States |
| Employees | 1350 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | TAC | DNLI |
|---|---|---|
| Price | $12.99 | $19.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 14 |
| Target Price | $23.67 | ★ $34.33 |
| AVG Volume (30 Days) | 952.2K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.48 | $408.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.73 | $12.58 |
| 52 Week High | $17.88 | $23.77 |
Technical Indicators
Market Signals| Indicator | TAC | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 47.06 |
| Support Level | $12.09 | $18.86 |
| Resistance Level | $14.00 | $20.35 |
| Average True Range (ATR) | 0.42 | 1.01 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 83.60 | 49.80 |
Price Performance
Historical ComparisonAbout TAC TransAlta Corporation
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.